New Capability at Pharmidex: Luminex xMAP INTELLIFLEX™
February 9, 2026

We’re excited to announce that Pharmidex has expanded its analytical capabilities with the addition of the xMAP INTELLIFLEX™ system, a powerful, high-performance platform for multiplex biomarker analysis.


This advanced technology enables the simultaneous measurement of multiple analytes from minimal sample volumes, delivering exceptional sensitivity, accuracy and reproducibility. It is ideally suited for complex biological matrices and supports a wide range of applications, from biomarker discovery to translational and preclinical studies. 



Our INTELLIFLEX™ supports dual reporter channels to collect more data per sample.


🔬 What this means for our partners and the wider scientific community:

• Faster, data-rich insights from fewer samples

• Enhanced assay flexibility and scalability

• Improved data quality to support confident decision-making

• Greater efficiency across drug discovery and development programmes


This investment strengthens Pharmidex’s commitment to scientific excellence, allowing us to deliver even more robust, innovative and reliable services to pharma, biotech, CROs and academic collaborators.


We look forward to putting this new capability to work in support of better science and better medicines.

#Pharmidex #Innovation #Biomarkers #Multiplexing #DrugDevelopment #LifeSciences #AnalyticalExcellence

👏 Congratulations to our collaborators on their recent publications

March 26, 2026
We are delighted to congratulate EpiEndo Pharmaceuticals and the Institute of Pharmaceutical Science, King's College London on the publication of two exciting studies exploring the therapeutic potential of EP395: 📄 “ The Effect of the Novel Macrolide Glasmacinal (EP395) on Allergen-Induced Eosinophil Infiltration into the Lung” published in "Lung" 📄 “Effects of EP395, a novel macrolide, on acute neutrophilic airway inflammation” published in "Pulmonary Pharmacology & Therapeutics" These studies provide valuable insights into the role of EP395 in modulating inflammatory responses in respiratory disease, supporting its potential as a novel therapeutic approach. At Pharmidex , we are proud to have contributed to this work through our Respiratory Department, supporting the in vivo studies and helping advance these important findings. We look forward to continuing our collaboration and supporting innovative programmes in respiratory drug discovery and development.

📢 New Publication from Pharmidex!

March 24, 2026
We are pleased to share our latest publication: “Magnetic field-induced drug delivery from magnetic microporous nanocomposites through magnetic nanoparticles heating or motion” , published in the journal Materials & Design . This work explores innovative approaches to magnetically triggered drug delivery, leveraging the unique properties of magnetic nanoparticles to enable controlled release through heating and motion mechanisms. These advances have the potential to open new avenues in targeted therapies and precision medicine. We would like to sincerely thank our collaborators for their valuable contributions to this research: -CRCT Université de Toulouse Inserm U1037 CNR -Laboratoire de Physique et Chimie des Nano-Objets (LPCNO) CNRS-UPS-INSA -Centro Singular de Investigación en Química Biológica y Materiales Moleculares (CIQUS) We are proud to contribute to cutting-edge research at the interface of nanotechnology and drug delivery and we look forward to continuing collaborations that drive innovation in drug discovery and development. 🔗 Read the full article: https://www.sciencedirect.com/science/article/pii/S0264127526003084?via%3Dihub

🌟 Pharmidex at the @Immuno-Oncology & Biomarker Summit 2026

March 16, 2026
Pharmidex is proud to be the Networking Sponsor at the Immuno-Oncology & Biomarker Summit in London. Over the next two days, the event provides an opportunity to discuss the latest advances in immuno-oncology, biomarker discovery, and precision medicine. If you’re attending, come and say hello to Ash Alavijeh to connect and explore opportunities to collaborate.
More Posts